JPRN-C000000427Completed未知
A Randomized Study of Angiotensin II Type 1 Receptor Blocker vs Dihydropidine Ca Antagonist for Treatment of Paroxysmal Atrial Fibrillation in Patients with Hypertension - J-RHYTHM II Study
The J-RHYTHM II Investigators0 sites400 target enrollmentStarted: July 10, 2006Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 400
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •The exclusion criteria are (1) normal BP (systolic/diastolic BP < 140/90 mmHg), (2) a history of vasospastic angina pectoris, (3) persistent AF with a duration of 1 week or longer, and/or permanent AF, (4) AF that has occurred within 1 month of the onset of myocardial infarction, (5) transient AF associated with cardiac surgery, (6) contraindication for anticoagulation therapy, (7) pregnancy or the possibility of pregnancy, and breast feeding, (8) patient age of 18 or less, and (9) a judgment by the attending physician that patient participation would be inappropriate
Investigators
Similar Trials
Completed
Not Applicable
Evaluation of the effect of AngiotensinII receptor blocker on coronary artery after Sirolimus-Eluting Stent implantatioJPRN-UMIN000001822Toyohashi Heart Ceter, Cardiovascular Medicine50
Completed
Phase 4
ong-term Effects of an Angiotensin II Type 1 Receptor Blocker in Hypertensive Patients with Chronic Kidney Disease and Metabolic SyndromeHypertension Chronic kidney disease Metabolic syndromeJPRN-UMIN000010892Department of Cardiology Kinu Medical Association Hospital160
Not yet recruiting
Not Applicable
Incidence of COVID-19 disease and the severity of SARS-CoV-2 infection and relationship with angiotensin II type 1 receptor (ATII-1R) concentration in healthcare professionals.ACTRN12621000013864Patrycja Lesnik, MD, PhD80
Recruiting
Phase 3
A randomized competitive trial of Angiotensin II Receptor Blocker (ARB) for prevention of tumor recurrence in non-muscle invasive bladder cancerBladder cancerJPRN-UMIN000005044Keio University Hospital200
Completed
Not Applicable
Prevention of complications after endoscopic retrograde cholangio-pancreaticography using the antihypertensive drug Cozaar®Post-endoscopic retrograde cholangio-pancreaticography pancreatitisDigestive SystemAcute pancreatitisISRCTN61320108Karolinska Institutet (Sweden)80